secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2026-03-11T23:59:59+00:00
Accession:  0001213900-26-025817
Event type: debt
Sentiment:  negative
Materiality: 0.50
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CERo Therapeutics issues $750K convertible note to Keystone Capital with conversion price floor at $0.05
--------------------------------------------------------------------------------

- Issued convertible promissory note to Keystone Capital Partners; purchase price $750,000, principal face value $937,500.
- Note bears 10% interest, matures August 6, 2027; conversion price is lesser of $0.05 or 80% of 5 lowest intraday prices in prior 20 days.
- Beneficial ownership limitation of 4.99%; company must file registration statement for resale of conversion shares.
- Offered under Section 4(a)(2) and Rule 506(b) exemption; no public offering.
- Maximum aggregate borrowing up to $1,000,000 under the note.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390026025817/0001213900-26-025817-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390026025817/ea0280905-8k_cero.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-025817

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer